Jumat, 01 Juni 2012

New Skin Transplant Method For Vitiligo Patients

New Skin Transplant Method For Vitiligo Patients

Editor's Choice
Main Category: Dermatology
Article Date: 01 Jun 2012 - 11:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions   <!-- rate icon rate article


Patient / Public:not yet rated

Healthcare Prof:not yet rated


In the United States, approximately 1 in 200 are affected by vitiligo - a skin disease that causes the skin to lose color and develop white patches. Now dermatologists at Henry Ford Hospital state that skin transplant surgery is safe and effective for restoring skin pigmentation caused by the disease.

The study is published in the Journal of the American Academy of Dermatology.

The team followed 23 patients who underwent the surgery for six months after the procedure. They found that, on average, the treated area of skin regained 43% of its natural color. Furthermore, in 8 patients with localized vitiligo, the treated skin area regained on average 68% of its natural color.

Performed under local anesthesia, the surgery, known as melanocyte-keratinocyte transplantation(MKTP), involves taking healthy skin cells from pigmented areas of the body and transferring them to the damaged area of skin.

Lead researcher of the study, Iltefat Hamzavi, M.D., a senior staff physician in Henry Ford's Department of Dermatology, said:

"The results achieved in our study were of obvious significance to our patients. We believe this new treatment option offers hope to patients of color and those with vitiligo on one side of the body or in one area of the body."

The skin disease develops when the body's immune system kills cells called melanocytes. These dead cells no longer make pigment and as a result the area of skin turns white. Although there is no cure for vitiligo, it can be managed and treated with topical medications, creams and light therapy.

Although the surgery is performed in Europe, the Middle East, and Asia, this is the first time the procedure has been performed in North America.

In the study, 28 patients aged 18 to 60 underwent MKTP. In total, the procedure was performed 36 times and the team examined the outcomes of 29 of them. Duration of the procedure lasted from 30 minutes to two hours. Patients where discharged from the hospital on the same day.

The researchers followed 23 of the 28 patients for up to 6 months. 18 patients received 1 treatment, 4 received two treatments and one patient received 3 treatments. The ethnicity of patients was Caucasian, South Asian, African American and Hispanic.

During the procedure, melanocyte cells are taken from an area of healthy skin and separated to make a skin cell mixture, which was then applied to the treatment area of the skin. The treated area, which was, on average, the size of a credit card, was then covered with a specially developed adhesive biologic dressing.

The study was a collaboration between Henry Ford and the National Center for Vitiligo, Riyadh, Saudi Arabia, and funded by the Shahani Foundation based in Michigan.

Written By Grace Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: The experience of an academic medical center in the United States
Richard H. Huggins, MD AFFILIATIONS Multicultural Dermatology Center, Department of Dermatology, Henry Ford Hospital, Detroit, Michigan , Marsha D. Henderson, MD, Sanjeev V. Mulekar, MD, David M. Ozog, MD, Holly A. Kerr, MD, Gordon Jabobsen, MS, Henry W. Lim, MD and Iltefat H. Hamzavi, MD
Journal of the American Academy of Dermatology, June 2012, doi:10.1016/j.jaad.2011.05.002 Please use one of the following formats to cite this article in your essay, paper or report:

MLA


APA

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'New Skin Transplant Method For Vitiligo Patients'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



MediLexicon International Ltd Logo

Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

Everyday Health Network back to top | home | privacy policy

MediLexicon International Ltd Logo MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

Tidak ada komentar:

Posting Komentar